+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Leukemia Therapeutics Market By Factor (Artificial ionizing radiation, Viruses, Chemotherapy, Genetics, Others), By Severity, By Blood Cell, By Age Groups, By Sex, By Treatment, By Diagnosis, By Route of Administration, By Drugs, By Region, Forecast & Opportunities, 2025

  • ID: 5031331
  • Report
  • May 2020
  • Region: Global
  • 110 pages
  • TechSci Research
UP TO OFF
until Jul 31st 2020
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now
The Global Leukemia Therapeutics Market is Driven by Innovations in the Field of Blood Cancer Testing on Account of the Growing Number of Patients Suffering from Leukemia.

FEATURED COMPANIES

  • Abbott
  • Astellas Pharma
  • Bristol-Myers Squibb
  • Eli Lilly
  • Johnson & Johnson
  • Otsuka Holdings
  • MORE
Leukemia or blood cancer is the cancer of blood forming tissues: bone marrow and lymphatic system. As the name suggests, it affects the leucocytes or white blood cells. In this type of cancer, the DNA of leucocytes gets damaged as a result of which they grow and divide uncontrollably. These cells keep on growing and start accumulating, thereby preventing the healthy white blood cells from growing and functioning.

The Global Leukemia Therapeutics Market is expected to grow at a formidable rate during the forecast period. The Global Leukemia Therapeutics Market is driven by the technological advancements and innovations in the field of blood cancer testing on account of the growing number of patients suffering from leukemia. Additionally, growing awareness among the population pertaining to adoption of preventive healthcare is further expected to propel the market during forecast period. Furthermore, supportive government initiatives & policies for promoting cancer awareness is anticipated to fuel the market growth until 2025.

The Global Leukemia Therapeutics Market can be segmented based on factor, severity, blood cell, age groups, sex, treatment, diagnosis, route of administration, drugs, company and region. Based on severity, the market can be bifurcated into acute and chronic. The chronic leukemia segment is expected to dominate the market during forecast period. This can be accredited to the rising geriatric population and increasing funding for cancer research and the development of new therapies.

Regionally, the Global Leukemia Therapeutics Market has been segmented into Asia-Pacific, North America, South America, Europe, and Middle East & Africa. Among these regions, North America is expected to dominate the market during forecast period. This can be attributed to the presence of a large geriatric population base in the country. Additionally, the presence of key players in the region is further expected to propel the market over 2025.

Major players operating in the Global Leukemia Therapeutics Market include Novartis, AbbVie, Bristol-Myers Squibb, Roche, Amgen, Gilead sciences, Celgene, Eisai, AstraZeneca, Incyte Corporation, Johnson & Johnson, Biogen, Merck, PerkinElmer, Eli Lilly, Abbott, Sumitomo Dainippon Pharma, Thermo Fisher Scientific, Otsuka Holdings, Astellas Pharma and others. The companies operating in the market are using organic strategies such as product launches, mergers and collaborations to boost their share. For instance, in August 2017, Bristol-Myers Squibb acquired IFM Therapeutics in order to fortify its oncology product line.

Years considered for this report:
  • Historical Years: 2015-2018
  • Base Year: 2019
  • Estimated Year: 2020
  • Forecast Period: 2021–2025
Objective of the Study:
  • To analyze and forecast the market size of the Global Leukemia Therapeutics Market.
  • To classify and forecast the Global Leukemia Therapeutics Market based on factor, severity, blood cell, age groups, sex, treatment, diagnosis, route of administration, drugs, company and regional distribution.
  • To identify drivers and challenges for the Global Leukemia Therapeutics Market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the Global Leukemia Therapeutics Market.
  • To identify and analyze the profile of leading players operating in the Global Leukemia Therapeutics Market.
The author performed both primary as well as exhaustive secondary research for this study. Initially, researchers sourced a list of manufacturers across the globe. Subsequently, researchers conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, researchers could include the manufacturers which could not be identified due to the limitations of secondary research. The author analyzed the manufacturers, distribution channels and presence of all major players across the globe.

The author calculated the market size of the Global Leukemia Therapeutics Market using a bottom-up approach, wherein the data for various end-user segments was recorded and forecast for the future years. The author sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.

Key Target Audience:
  • Leukemia therapeutics manufacturers, suppliers, distributors and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to leukemia therapeutics
  • Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, end-users, etc., besides allowing them in strategizing investments and capitalizing on the market opportunities.

Report Scope:
In this report, the Global Leukemia Therapeutics Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Market, By Factor:
  • Artificial ionizing radiation
  • Viruses
  • Chemotherapy
  • Genetics
  • Immune suppression
  • Others
Market, By Severity:
  • Acute
  • Chronic
Market, By Blood Cell:
  • Lymphocytic
  • Myelogenous
Market, By Age Groups:
  • 0-15
  • 15-30
  • 30-50
  • 50+
Market, By Sex:
  • Male
  • Female
Market, By Treatment:
  • Targeted Therapy
  • Interferon Therapy
  • Radiation Therapy
  • Surgery
  • Stem Cell Transplantation
  • Drugs
  • Gene Therapy
  • Immunotherapy
  • Vaccine Therapy
  • Chemotherapy
  • Blood Transfusion
Market, By Diagnosis:
  • Blood test
  • Biopsy
  • Physical Exam
  • Imagining
  • CT-SCAN
  • X-RAY
  • MRI
Market, By Route of Administration:
  • Oral
  • Intravenous
  • Subcutaneous
  • Intramuscular
  • Intrathecal
Market, By Drugs:
  • Antimetabolites
  • Biosimilars
  • Asparagine-Specific Enzymes
  • Hormones (Corticosteroids)
  • Hypomethylating (Demethylating) Agents
  • Tyrosine Kinase Inhibitors
  • Others
Market, By Region:
  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Australia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • South America
  • Brazil
  • Argentina
  • Colombia
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Leukemia Therapeutics Market.

Available Customizations:
With the given market data, the author offers customizations according to a client’s specific needs.

This report is 80% complete and can be delivered within three working days post order confirmation and will include the latest impact analysis of Covid-19 in 2020 and forecast. If you buy the ‘Multi-user’ License of this report before June 2020, you will get a free update in form of market data excel sheet within 3 to 6 months of your purchase on request.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abbott
  • Astellas Pharma
  • Bristol-Myers Squibb
  • Eli Lilly
  • Johnson & Johnson
  • Otsuka Holdings
  • MORE
1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Leukemia Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value & Volume
5.2. Market Share & Forecast
5.2.1. By Factor (Artificial ionizing radiation, Viruses, Chemotherapy, Genetics, Immune suppression, Others)
5.2.2. By Severity (Acute, Chronic)
5.2.3. By Blood Cell (Lymphocytic, Myelogenous)
5.2.4. By Age Groups (0-15, 15-30, 30-50, 50+)
5.2.5. By Sex (Male, Female)
5.2.6. By Treatment (Targeted Therapy, Interferon Therapy, Radiation Therapy, Surgery, Stem Cell Transplantation, Drugs, Gene Therapy, Immunotherapy, Vaccine Therapy, Chemotherapy, Blood Transfusion)
5.2.7. By Diagnosis (Blood test, Biopsy, Physical Exam, Imagining (CT-SCAN, X-RAY, MRI))
5.2.8. By Route of Administration (Oral, Intravenous, Subcutaneous, Intramuscular, Intrathecal)
5.2.9. By Drugs (Antimetabolites, Biosimilars, Asparagine-Specific Enzymes, Hormones (Corticosteroids), Hypomethylating (Demethylating) Agents, Tyrosine Kinase Inhibitors, Others)
5.2.10. By Company (2019)
5.2.11. By Region
5.3. Market Attractiveness Index

6. Asia-Pacific Leukemia Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value & Volume
6.2. Market Share & Forecast
6.2.1. By Factor
6.2.2. By Severity
6.2.3. By Blood Cell
6.2.4. By Age Groups
6.2.5. By Sex
6.2.6. By Treatment
6.2.7. By Diagnosis
6.2.8. By Route of Administration
6.2.9. By Drugs
6.2.10. By Country
6.3. Market Attractiveness Index
6.4. Asia-Pacific: Country Analysis
6.4.1. China Leukemia Therapeutics Market Outlook
6.4.1.1. Market Size & Forecast
6.4.1.1.1. By Value
6.4.1.2. Market Share & Forecast
6.4.1.2.1. By Factor
6.4.1.2.2. By Severity
6.4.1.2.3. By Blood Cell
6.4.1.2.4. By Age Groups
6.4.1.2.5. By Sex
6.4.1.2.6. By Treatment
6.4.1.2.7. By Diagnosis
6.4.1.2.8. By Route of Administration
6.4.1.2.9. By Drugs
6.4.2. India Leukemia Therapeutics Market Outlook
6.4.2.1. Market Size & Forecast
6.4.2.1.1. By Value
6.4.2.2. Market Share & Forecast
6.4.2.2.1. By Factor
6.4.2.2.2. By Severity
6.4.2.2.3. By Blood Cell
6.4.2.2.4. By Age Groups
6.4.2.2.5. By Sex
6.4.2.2.6. By Treatment
6.4.2.2.7. By Diagnosis
6.4.2.2.8. By Route of Administration
6.4.2.2.9. By Drugs
6.4.3. Japan Leukemia Therapeutics Market Outlook
6.4.3.1. Market Size & Forecast
6.4.3.1.1. By Value
6.4.3.2. Market Share & Forecast
6.4.3.2.1. By Factor
6.4.3.2.2. By Severity
6.4.3.2.3. By Blood Cell
6.4.3.2.4. By Age Groups
6.4.3.2.5. By Sex
6.4.3.2.6. By Treatment
6.4.3.2.7. By Diagnosis
6.4.3.2.8. By Route of Administration
6.4.3.2.9. By Drugs
6.4.4. South Korea Leukemia Therapeutics Market Outlook
6.4.4.1. Market Size & Forecast
6.4.4.1.1. By Value
6.4.4.2. Market Share & Forecast
6.4.4.2.1. By Factor
6.4.4.2.2. By Severity
6.4.4.2.3. By Blood Cell
6.4.4.2.4. By Age Groups
6.4.4.2.5. By Sex
6.4.4.2.6. By Treatment
6.4.4.2.7. By Diagnosis
6.4.4.2.8. By Route of Administration
6.4.4.2.9. By Drugs
6.4.5. Singapore Leukemia Therapeutics Market Outlook
6.4.5.1. Market Size & Forecast
6.4.5.1.1. By Value
6.4.5.2. Market Share & Forecast
6.4.5.2.1. By Factor
6.4.5.2.2. By Severity
6.4.5.2.3. By Blood Cell
6.4.5.2.4. By Age Groups
6.4.5.2.5. By Sex
6.4.5.2.6. By Treatment
6.4.5.2.7. By Diagnosis
6.4.5.2.8. By Route of Administration
6.4.5.2.9. By Drugs
6.4.6. Australia Leukemia Therapeutics Market Outlook
6.4.6.1. Market Size & Forecast
6.4.6.1.1. By Value
6.4.6.2. Market Share & Forecast
6.4.6.2.1. By Factor
6.4.6.2.2. By Severity
6.4.6.2.3. By Blood Cell
6.4.6.2.4. By Age Groups
6.4.6.2.5. By Sex
6.4.6.2.6. By Treatment
6.4.6.2.7. By Diagnosis
6.4.6.2.8. By Route of Administration
6.4.6.2.9. By Drugs

7. Europe Leukemia Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value & Volume
7.2. Market Share & Forecast
7.2.1. By Factor
7.2.2. By Severity
7.2.3. By Blood Cell
7.2.4. By Age Groups
7.2.5. By Sex
7.2.6. By Treatment
7.2.7. By Diagnosis
7.2.8. By Route of Administration
7.2.9. By Drugs
7.2.10. By Country
7.3. Market Attractiveness Index
7.4. Europe: Country Analysis
7.4.1. France Leukemia Therapeutics Market Outlook
7.4.1.1. Market Size & Forecast
7.4.1.1.1. By Value
7.4.1.2. Market Share & Forecast
7.4.1.2.1. By Factor
7.4.1.2.2. By Severity
7.4.1.2.3. By Blood Cell
7.4.1.2.4. By Age Groups
7.4.1.2.5. By Sex
7.4.1.2.6. By Treatment
7.4.1.2.7. By Diagnosis
7.4.1.2.8. By Route of Administration
7.4.1.2.9. By Drugs
7.4.2. Germany Leukemia Therapeutics Market Outlook
7.4.2.1. Market Size & Forecast
7.4.2.1.1. By Value
7.4.2.2. Market Share & Forecast
7.4.2.2.1. By Factor
7.4.2.2.2. By Severity
7.4.2.2.3. By Blood Cell
7.4.2.2.4. By Age Groups
7.4.2.2.5. By Sex
7.4.2.2.6. By Treatment
7.4.2.2.7. By Diagnosis
7.4.2.2.8. By Route of Administration
7.4.2.2.9. By Drugs
7.4.3. United Kingdom Leukemia Therapeutics Market Outlook
7.4.3.1. Market Size & Forecast
7.4.3.1.1. By Value
7.4.3.2. Market Share & Forecast
7.4.3.2.1. By Factor
7.4.3.2.2. By Severity
7.4.3.2.3. By Blood Cell
7.4.3.2.4. By Age Groups
7.4.3.2.5. By Sex
7.4.3.2.6. By Treatment
7.4.3.2.7. By Diagnosis
7.4.3.2.8. By Route of Administration
7.4.3.2.9. By Drugs
7.4.4. Italy Leukemia Therapeutics Market Outlook
7.4.4.1. Market Size & Forecast
7.4.4.1.1. By Value
7.4.4.2. Market Share & Forecast
7.4.4.2.1. By Factor
7.4.4.2.2. By Severity
7.4.4.2.3. By Blood Cell
7.4.4.2.4. By Age Groups
7.4.4.2.5. By Sex
7.4.4.2.6. By Treatment
7.4.4.2.7. By Diagnosis
7.4.4.2.8. By Route of Administration
7.4.4.2.9. By Drugs

8. North America Leukemia Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value & Volume
8.2. Market Share & Forecast
8.2.1. By Factor
8.2.2. By Severity
8.2.3. By Blood Cell
8.2.4. By Age Groups
8.2.5. By Sex
8.2.6. By Treatment
8.2.7. By Diagnosis
8.2.8. By Route of Administration
8.2.9. By Drugs
8.2.10. By Country
8.3. Market Attractiveness Index
8.4. North America: Country Analysis
8.4.1. United States Leukemia Therapeutics Market Outlook
8.4.1.1. Market Size & Forecast
8.4.1.1.1. By Value
8.4.1.2. Market Share & Forecast
8.4.1.2.1. By Factor
8.4.1.2.2. By Severity
8.4.1.2.3. By Blood Cell
8.4.1.2.4. By Age Groups
8.4.1.2.5. By Sex
8.4.1.2.6. By Treatment
8.4.1.2.7. By Diagnosis
8.4.1.2.8. By Route of Administration
8.4.1.2.9. By Drugs
8.4.2. Mexico Leukemia Therapeutics Market Outlook
8.4.2.1. Market Size & Forecast
8.4.2.1.1. By Value
8.4.2.2. Market Share & Forecast
8.4.2.2.1. By Factor
8.4.2.2.2. By Severity
8.4.2.2.3. By Blood Cell
8.4.2.2.4. By Age Groups
8.4.2.2.5. By Sex
8.4.2.2.6. By Treatment
8.4.2.2.7. By Diagnosis
8.4.2.2.8. By Route of Administration
8.4.2.2.9. By Drugs
8.4.3. Canada Leukemia Therapeutics Market Outlook
8.4.3.1. Market Size & Forecast
8.4.3.1.1. By Value
8.4.3.2. Market Share & Forecast
8.4.3.2.1. By Factor
8.4.3.2.2. By Severity
8.4.3.2.3. By Blood Cell
8.4.3.2.4. By Age Groups
8.4.3.2.5. By Sex
8.4.3.2.6. By Treatment
8.4.3.2.7. By Diagnosis
8.4.3.2.8. By Route of Administration
8.4.3.2.9. By Drugs

9. South America Leukemia Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value & Volume
9.2. Market Share & Forecast
9.2.1. By Factor
9.2.2. By Severity
9.2.3. By Blood Cell
9.2.4. By Age Groups
9.2.5. By Sex
9.2.6. By Treatment
9.2.7. By Diagnosis
9.2.8. By Route of Administration
9.2.9. By Drugs
9.2.10. By Country
9.3. Market Attractiveness Index
9.4. South America: Country Analysis
9.4.1. Brazil Leukemia Therapeutics Market Outlook
9.4.1.1. Market Size & Forecast
9.4.1.1.1. By Value
9.4.1.2. Market Share & Forecast
9.4.1.2.1. By Factor
9.4.1.2.2. By Severity
9.4.1.2.3. By Blood Cell
9.4.1.2.4. By Age Groups
9.4.1.2.5. By Sex
9.4.1.2.6. By Treatment
9.4.1.2.7. By Diagnosis
9.4.1.2.8. By Route of Administration
9.4.1.2.9. By Drugs
9.4.2. Argentina Leukemia Therapeutics Market Outlook
9.4.2.1. Market Size & Forecast
9.4.2.1.1. By Value
9.4.2.2. Market Share & Forecast
9.4.2.2.1. By Factor
9.4.2.2.2. By Severity
9.4.2.2.3. By Blood Cell
9.4.2.2.4. By Age Groups
9.4.2.2.5. By Sex
9.4.2.2.6. By Treatment
9.4.2.2.7. By Diagnosis
9.4.2.2.8. By Route of Administration
9.4.2.2.9. By Drugs
9.4.3. Colombia Leukemia Therapeutics Market Outlook
9.4.3.1. Market Size & Forecast
9.4.3.1.1. By Value
9.4.3.2. Market Share & Forecast
9.4.3.2.1. By Factor
9.4.3.2.2. By Severity
9.4.3.2.3. By Blood Cell
9.4.3.2.4. By Age Groups
9.4.3.2.5. By Sex
9.4.3.2.6. By Treatment
9.4.3.2.7. By Diagnosis
9.4.3.2.8. By Route of Administration
9.4.3.2.9. By Drugs

10. Middle East and Africa Leukemia Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value & Volume
10.2. Market Share & Forecast
10.2.1. By Factor
10.2.2. By Severity
10.2.3. By Blood Cell
10.2.4. By Age Groups
10.2.5. By Sex
10.2.6. By Treatment
10.2.7. By Diagnosis
10.2.8. By Route of Administration
10.2.9. By Drugs
10.2.10. By Country
10.3. Market Attractiveness Index
10.4. MEA: Country Analysis
10.4.1. South Africa Leukemia Therapeutics Market Outlook
10.4.1.1. Market Size & Forecast
10.4.1.1.1. By Value
10.4.1.2. Market Share & Forecast
10.4.1.2.1. By Factor
10.4.1.2.2. By Severity
10.4.1.2.3. By Blood Cell
10.4.1.2.4. By Age Groups
10.4.1.2.5. By Sex
10.4.1.2.6. By Treatment
10.4.1.2.7. By Diagnosis
10.4.1.2.8. By Route of Administration
10.4.1.2.9. By Drugs
10.4.2. Saudi Arabia Leukemia Therapeutics Market Outlook
10.4.2.1. Market Size & Forecast
10.4.2.1.1. By Value
10.4.2.2. Market Share & Forecast
10.4.2.2.1. By Factor
10.4.2.2.2. By Severity
10.4.2.2.3. By Blood Cell
10.4.2.2.4. By Age Groups
10.4.2.2.5. By Sex
10.4.2.2.6. By Treatment
10.4.2.2.7. By Diagnosis
10.4.2.2.8. By Route of Administration
10.4.2.2.9. By Drugs
10.4.3. UAE Leukemia Therapeutics Market Outlook
10.4.3.1. Market Size & Forecast
10.4.3.1.1. By Value
10.4.3.2. Market Share & Forecast
10.4.3.2.1. By Factor
10.4.3.2.2. By Severity
10.4.3.2.3. By Blood Cell
10.4.3.2.4. By Age Groups
10.4.3.2.5. By Sex
10.4.3.2.6. By Treatment
10.4.3.2.7. By Diagnosis
10.4.3.2.8. By Route of Administration
10.4.3.2.9. By Drugs

11. Market Dynamics
11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape
13.1. Competition Outlook
13.2. Players Profiled (Leading Companies)
13.2.1. Novartis
13.2.2. AbbVie
13.2.3. Bristol-Myers Squibb
13.2.4. Roche
13.2.5. Amgen
13.2.6. Gilead sciences
13.2.7. Celgene
13.2.8. Eisai
13.2.9. AstraZeneca
13.2.10. Incyte Corporation
13.2.11. Johnson & Johnson
13.2.12. Biogen
13.2.13. Merck
13.2.14. PerkinElmer
13.2.15. Eli Lilly
13.2.16. Abbott
13.2.17. Sumitomo Dainippon Pharma
13.2.18. Thermo Fisher Scientific
13.2.19. Otsuka Holdings
13.2.20. Astellas Pharma

14. Strategic Recommendations

15. About the author & Disclaimer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Novartis
  • AbbVie
  • Bristol-Myers Squibb
  • Roche
  • Amgen
  • Gilead sciences
  • Celgene
  • Eisai
  • AstraZeneca
  • Incyte Corporation
  • Johnson & Johnson
  • Biogen
  • Merck
  • PerkinElmer
  • Eli Lilly
  • Abbott
  • Sumitomo Dainippon Pharma
  • Thermo Fisher Scientific
  • Otsuka Holdings
  • Astellas Pharma
Note: Product cover images may vary from those shown
Adroll
adroll